Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer.
Conteduca V, et al. Br J Cancer. 2020
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.
Conteduca V, et al. JCO Precision Oncology. 2020
Genome-wide plasma DNA methylation features of metastatic prostate cancer.
Wu A, et al. The Journal of Clinical Investigation. 2020
Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.
Jayaram A, et al. JCO Precision Oncology. 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V, et al. European Urology. 2018
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V, et al. Ann Oncol. 2017
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
McDaniel AS, et al. BJU Int. 2017
Plasma AR and abiraterone-resistant prostate cancer.
Romanel A, et al. Sci Transl Med. 2015
Androgen receptor expression in circulating tumour cells from castration resistant prostate cancer patients treated with novel endocrine agents.
Crespo M, et al. Br J Cancer. 2015
Tumor clone dynamics in lethal prostate cancer.
Carreira S, et al. Sci Transl Med. 2014
Clinical trials and international collaborations
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Clarke N, et al. Ann. Oncol. 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.
Attard G, et al. JAMA Oncology. 2019
Sequencing of agents in castration-resistant prostate cancer.
Lorente D, et al. Lancet Oncol. 2015
Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Attard G, et al. Clin Cancer Res. 2015
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J, et al. Cancer Res. 2012
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
Gilson C, et al. JCO Precision Oncology. 2020
P - 182 Tumour Infiltrating Lymphocytes assessment in the STAMPEDE cohort: association of brisk inflammation with high grade histology.
Mendes L, et al. EACR-AACR-ASPIC Tum Microenvironment 2020
153 Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis.
Grist E, et al. J Clin Oncol 2020
39 Copy number profiling of STAMPEDE trial patients to improve targeting of existing therapies for advanced hormone-sensitive prostate cancer.
Grist E, et al. EACR Cancer Genomics Conference 2019
88 Whole genome expression analysis of diagnostic patient samples enrolled in the STAMPEDE clinical trial in advanced prostate cancer.
Parry M, et al. EACR Cancer Genomics Conference 2019
29P - Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium
Grist E, et al. Ann. Oncol. 2018
Editorials and Reviews
Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management.
Wu A, Attard G. Clin Chem 2019.
Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.
Jayaram A, Wetterskog D, Attard G, Cancer Discov. 2018.